The Pharma Data

JULY 11, 2021

The efficacy of TAKHZYRO to prevent HAE attacks over the long term will be an important consideration for patients and physicians as they develop a treatment plan for patients that is focused on reducing the number of HAE attacks.”. Markus Magerl, M.D., Vice President, Global Medical Head, HAE and Transplant at Takeda. Interactions.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

The Pharma Data

JANUARY 27, 2021

Avacta has worked with Adeptrix Inc (Beverly, MA, USA) to develop a coronavirus antigen test that combines enrichment of the sample using Affimer® reagents with the analytical power of mass-spectrometry. Beverley, MA) (“Adeptrix”). I look forward to updating the market when we have definitive clinical performance data.”.

Reagent 52

Reagent In-Vitro FDA Approval Development 52

Drug Discovery World

JANUARY 19, 2023

Plasmid DNA: a critical reagent pDNA is the starting material for the development of many cell and gene therapy products, irrespective of the mode of action. Figure 1 shows the development pathways for non-viral and viral vector gene therapies, and cell therapy and illustrates the critical role pDNA plays in their development.

DNA 52

DNA Manufacturing Gene Therapy Gene 52

Roots Analysis

FEBRUARY 13, 2023

Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. In addition to this, more than 95 mRNA synthesis kits, that contain reagents for the synthesis of research grade mRNAs, are currently available in the market.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

Drug Discovery World

OCTOBER 21, 2022

Accordingly, advances in flow cytometry technology – both in instrumentation and reagent offerings – are enabling researchers to decipher these questions, leading to new discoveries and diagnostic tools. . Best antibody development practices are summarised in Fig. Overview, evolution, trends .

Reagent 52

Reagent Antibody Drugs Protein 52

The Pharma Data

DECEMBER 2, 2020

Howard Mayer, Ipsen’s head of research and development, called the Fast Track designation for Onivyde “an extension of Ipsen’s focus and contribution” to the oncology landscape. The goal is to develop a first-in-class treatment for Staphylococcus aureus infections and thereby prevent exacerbation of pneumonia.

Drugs 52

Drugs Gene Editing Genome Genomics 52

FDA Law Blog

NOVEMBER 1, 2023

Gibbs — For more than three decades, FDA has claimed that the Federal Food, Drug & Cosmetic (FD&C Act) gives the agency legal authority to regulate laboratory developed tests (LDTs) as medical devices (see our prior post here ). Gaulkin & Jeffrey N.

Regulation 81

Regulation In-Vitro Manufacturing Licensing 81

Roots Analysis

OCTOBER 16, 2023

Further, DNA contains some specific patterns of nucleic acid sequences, for instance, transcription factors as DNA binding sites for a regulatory protein, known as motifs. Further, the labor and reagent cost incurred in cloning procedures is reduced with customized cloning.

DNA 40

DNA Gene Protein In-Vitro 40

Drug Discovery World

NOVEMBER 30, 2023

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. GSK has developed high-throughput mammalian and E.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

OCTOBER 12, 2022

Professor Michael Butler, head of the National Institute for Bioprocessing Research and Training (NIBRT) Cell Technology Group (CTG), explains that the characterisation and analysis of glycans is important for the biopharma sector as it can help in the development of therapeutic agents such as monoclonal antibodies and other recombinant proteins.

Protein 52

Protein Gene Therapy Antibody Production 52

Drug Discovery World

JUNE 14, 2023

BCA members also operate the BCA Advanced Therapies Network which is a diverse, fully integrated portfolio of blood, cell, gene and tissue materials that support the development and delivery of advanced therapies. BCA and its members are developing innovative ways to attract younger donors through the use of technology.

Manufacturing 52

Manufacturing Production Gene Therapy Development 52

The Pharma Data

JANUARY 20, 2021

Laboratory Implementation Laboratory reagents for performing the test commercially have been designed and are currently being validated in preparation for regulatory submission to CMS/CLIA with a view to targeting sales in the USA initially. MELBOURNE, Australia, Jan. Key Highlights. Quarterly Results Release Date and Webinar.

Genetics 52

Genetics Reagent Biobanking Production 52

Drug Discovery World

AUGUST 12, 2022

By selecting the correct salt form for an assay or as a reagent, scientists can optimise their research projects, says Andrievs Auseklis Auzin, Developer, Molport, Latvia. As an example, one salt analysis algorithm developed by aggregator MolPort proceeds stepwise: a. The research chemical supply market. In a text field only.

Drugs 52

Drugs Bioassay Development Research 52

Drug Discovery World

FEBRUARY 8, 2023

Partially-filled capsids may also be present, and contain packaged process-related impurities or truncated genetic material. As such, characterising the proportions of empty, partially-filled, and full AAV capsids is vital for determining sample quality and estimating efficacy during both process development and for quality control.

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

Drug Discovery World

DECEMBER 15, 2022

Possible solutions: A new generation of gene editing tools is being developed to avoid double stranded breaks altogether and to be potentially less destructive than traditional nuclease systems. Topping the list of alternatives are lipid nanoparticles (LNPs) and electroporation.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

OCTOBER 14, 2022

Reducing assay volumes from about 200 µL to 1 µL ha s cut the quantities of reagents and consumables needed, while automation has replaced manual handling, so lowering running and personnel costs. . A recently developed technique of laser induced post-ionization 21 further extend s the chemical space accessible in HTE synthesis monitoring.

Drugs 52

Drugs In-Vitro Development Production 52